Quanterix (QTRX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
8 May, 2026Executive summary
The annual meeting is scheduled for June 9, 2026, and will be held virtually for shareholder participation.
The proxy supplement updates Proposal No. 4 regarding amendments to the 2017 Equity Incentive Plan, reinstating and adding award limitations.
All other information in the original proxy statement remains unchanged except as updated by this supplement.
Voting matters and shareholder proposals
Shareholders will vote on the election of directors, executive compensation (say-on-pay), ratification of KPMG LLP as auditor, and approval of the amended 2017 Equity Incentive Plan.
Proposal No. 4 amends the 2017 Plan to reinstate a per-participant annual share award limit and adds a cap on non-employee director compensation.
Proxy cards already submitted remain valid; no new cards are required due to the supplement.
Board of directors and corporate governance
The Board recommends voting FOR all director nominees and FOR all proposals.
The Board delegated authority to officers and the Compensation Committee Chair to approve amendments to the equity plan.
Latest events from Quanterix
- Diagnostics and clinical trials growth, new leadership, and synergy gains drive optimism for 2024.QTRX
Canaccord Genuity's 46th Annual Growth Conference - Q2 2026 revenue up 34% YoY, but guidance cut and breakeven delayed amid execution and market headwinds.QTRX
Q2 2026 - Blood-based diagnostics gain momentum as early detection and monitoring become central to Alzheimer's care.QTRX
Goldman Sachs 45th Annual Global Healthcare Conference - Diagnostics expansion and innovation set to drive growth and cash flow breakeven in H2.QTRX
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Q1 2026 revenue up 20% to $36.4M, with improved margins and $85M in cost synergies.QTRX
Q1 2026 - Diagnostics and diversification drive growth as financial discipline and innovation strengthen outlook.QTRX
Leerink Global Healthcare Conference 2026 - Annual meeting to vote on directors, executive pay, auditor, and equity plan amendment.QTRX
Proxy filing - Q3 2024 revenue rose 13% to $35.8M; guidance reaffirmed and Emission Inc. acquisition announced.QTRX
Q3 2024 - Record consumables and cost cuts offset revenue decline as Akoya merger and Simoa ONE advance.QTRX
Q1 2025